Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status-Reference-Cited by-同舟云学术

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

Published:2020-06 Issue:3 Volume:3 Page:351-359
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Grivas Petros,Plimack Elizabeth R.^ORCID,Balar Arjun V.,Castellano Daniel,O’Donnell Peter H.,Bellmunt Joaquim,Powles Thomas,Hahn Noah M.,de Wit Ronald,Bajorin Dean F.,Ellison Misoo C.,Frenkl Tara L.^ORCID,Godwin James L.^ORCID,Vuky Jacqueline

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference23 articles.

1. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection;Wong;Sci Rep,2018

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

3. Urothelial carcinoma management in elderly or unfit patients;Bellmunt;EJC Suppl,2016

4. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

5. Bladder cancer in the elderly patient: challenges and solutions;Guancial;Clin Interv Aging,2015

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group;Frontiers in Oncology;2024-07-04

2. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma;Frontiers in Immunology;2024-05-10

3. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy;Cancers;2024-02-23

4. The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma;BMC Cancer;2024-02-13

5. An iodine‑labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma;International Journal of Pharmaceutics;2024-02